What is RVMDW's market cap?

$89.98M, based on the Nov 12 close of $8.15.

What sector is RVMDW in?

Healthcare, in the Biotechnology industry.

NASDAQ · RVMDWHealthcareBiotechnology

Revolution Medicines, Inc. Warrant (RVMDW)

$8.15−5.78%

Close Nov 12, 2026 · split-adjusted

Nov 12, 2026$8.15▲ 1937.50% in range

Nov 12, 2025Low $0.40 · High $13.26Nov 12, 2026

What changed · written from our data

As of Nov 12, 2026

Revolution Medicines, Inc. Warrant closed at $8.15 on Nov 12, down 5.78%, 38.5% below its 52-week closing high. Volume of 8.2K shares was 0.45× its 20-day average (below normal).

Split-adjusted performance: -18.5% over one month, +45.8% over six months, +1937.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $197.56M, with a net margin of -206.2%.

Short interest was 1.3K shares at the Oct 30 settlement, down 15.9% from the prior report (1.0 days to cover).

Market cap$90.0M11.0M shares

Revenue · quarter$197.6M—

Diluted EPS$-1.90—

P/E · TTM—P/S 0.5×

Net margin-206.2%Gross 99.8%

Dividend yieldNone

52-week range0.40 – 13.26−38.5% from high

Volume8.2K0.45× 20-day avg

Volatility · 60d109.3%Annualised

Short % of float—1.0 days to cover

Net cash$3.16BCash $3.65B

Next earnings—Not scheduled

Split-adjusted performance

1W −4.1%1M −18.5%3M −26.6%6M +45.8%YTD +767.1%1Y +1937.5%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −24.5%, revenue growth +4.6%, net margin −221.0%, P/E 19.3×.

Short interest

Details →

Shares short1.3K−15.9% vs prior

Days to cover1.0Settled Oct 30

% of float—

Short vol. 10d31.5%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RVMDWRevolution Medicines, Inc. Warrant	$8.15	−5.78%	+45.8%	—	−206.2%	—	$90.0M
TVGNWTevogen Inc. Warrant	$0.0412	+0.49%	−2.6%	—	—	—	$740.6K	Compare
ESLAWEstrella Immunopharma, Inc. Warrant	$0.0702	+12.32%	—	—	—	—	$155.5K	Compare

News about Revolution Medicines, Inc. Warrant

All news →

Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a BetZacks Investment Research · 3d ago▲ Positive Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?The Motley Fool · 4d ago▲ Positive Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer DrugThe Motley Fool · 5d ago▲ Positive Could Revolution Medicines Be a Millionaire-Maker Stock?The Motley Fool · Oct 29, 2026▲ Positive Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?The Motley Fool · Oct 27, 2026▲ Positive

Quick answers

What does Revolution Medicines, Inc. Warrant do?: Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
What is RVMDW's market cap?: $89.98M, based on the Nov 12 close of $8.15.
What sector is RVMDW in?: Healthcare, in the Biotechnology industry.

About Revolution Medicines, Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

HQ: Redwood City, CA883 employeesListed Nov 17, 2023revmed.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology